![](/wp-content/uploads/2018/10/qrh8kRaKRuu2Uthwu8z4.png)
$599
Medtronic CY Q4 ’20 (FY Q3 ’21) Earnings Update
Medtronic hosted its CY Q4 ’20 (FY Q3 ’21) earnings call (press release; slides) and provided updates to its diabetes business across the 780G advanced hybrid closed-loop system (AHCL) and next-gen CGM platforms (Zeus and Synergy CGM). Below, FENIX provides highlights and insights from the call, including thoughts on Medtronic’s evolving CGM pipeline.